• Policy
• Benefit for 46 generics for Eliquis will be kicked out
• by Kim, Jung-Ju Nov 22, 2021 05:52am

• Policy
• Lixiana latecomers apply for approval as an ODT
• by Lee, Tak-Sun Nov 22, 2021 05:52am

• Company
• Prolonged delay in GSK vaccine supply may cost ₩30 bil
• by Nov 22, 2021 05:52am

• Company
• Yuhan has secured 260 billion won in technology fee in 3 yrs
• by Chon, Seung-Hyun Nov 22, 2021 05:52am

• Company
• Viatris Korea will participate in the IMPACT WEEK
• by Eo, Yun-Ho Nov 22, 2021 05:52am

• Policy
• AML drug that returned after 7 years is approved in Korea
• by Lee, Tak-Sun Nov 19, 2021 05:52am

• Policy
• The CSO reporting system will be reviewed
• by Lee, Jeong-Hwan Nov 19, 2021 05:52am

• Policy
• Is Celltrion developing a combination of HBP?
• by Lee, Tak-Sun Nov 19, 2021 05:51am

• Policy
• Competition intensifies in Forsteo market with 4 latecomers
• by Lee, Tak-Sun Nov 19, 2021 05:51am

• Policy
• A law, proposed to prohibit overuse of drug price reduction
• by Lee, Jeong-Hwan Nov 19, 2021 05:51am